Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells

Resistance to chemotherapy and a high relapse rate highlight the importance of finding new therapeutic options for the treatment of acute myeloid leukemia (AML). Histone deacetylase (HDAC) inhibitors (HDACIs) are a promising class of drugs for the treatment of AML. HDACIs have limited single-agent c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jianyun, Xie, Chengzhi, Edwards, Holly, Wang, Guan, Taub, Jeffrey W, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351634/
https://www.ncbi.nlm.nih.gov/pubmed/28030834
http://dx.doi.org/10.18632/oncotarget.14062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351634/
https://www.ncbi.nlm.nih.gov/pubmed/28030834
http://dx.doi.org/10.18632/oncotarget.14062

Ejemplares similares